Tailwinds propel life science sector forward over the long term
Sentiment for the life sciences sector reached a fever pitch during the COVID-19 pandemic; global attention turned to the biopharma industry as it mobilized in record time to deliver life-saving vaccines. This unprecedented success was the culmination of decades of research performed in just a handful of laboratory clusters in select cities across the U.S.
Independent of the pandemic, life science research has been fueled by other macroeconomic tailwinds. The rapidly aging global population has demanded and will continue to demand breakthroughs in therapies and treatments for degenerative diseases that are more prevalent with age. This megatrend has led to record levels of both public and private funding for the biopharma industry and unprecedented demand for laboratory R&D space.
- Funding for medical research
- Demographic drivers
- Life science market disruption
- 2023 banner year for life sciences M&A
- New supply testing the market
- Investing in life science